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Cardiac myosin is the molecular motor that powers heart
contraction by converting chemical energy from ATP hydrolysis into mechanical force. The power output of the heart is
tightly regulated to meet the physiological needs of the body.
Recent multiscale studies spanning from molecules to tissues
have revealed complex regulatory mechanisms that ﬁne-tune
cardiac contraction, in which myosin not only generates power output but also plays an active role in its regulation. Thus,
myosin is both shaped by and actively involved in shaping its
mechanical environment. Moreover, these studies have shown
that cardiac myosin-generated tension affects physiological
processes beyond muscle contraction. Here, we review these
novel regulatory mechanisms, as well as the roles that myosinbased force generation and mechanotransduction play in
development and disease. We describe how key intra- and
intermolecular interactions contribute to the regulation of
myosin-based contractility and the role of mechanical forces in
tuning myosin function. We also discuss the emergence of
cardiac myosin as a drug target for diseases including heart
failure, leading to the discovery of therapeutics that directly
tune myosin contractility. Finally, we highlight some of the
outstanding questions that must be addressed to better understand myosin’s functions and regulation, and we discuss
prospects for translating these discoveries into precision
medicine
therapeutics
targeting
contractility
and
mechanotransduction.

Cardiac myosin is best known as the molecular motor that
powers heart contraction. It is a member of the myosin II
family (also known as conventional myosin), which includes
two-headed, ﬁlament-forming muscle and nonmuscle myosins. Although this “conventional” myosin has been studied
for several decades, recent studies have revealed novel functions and regulatory mechanisms that are anything but conventional. It has become clear that cardiac myosin not only
powers heart contraction but also plays pivotal roles in
muscle regulation, development, and mechanotransduction.
Dysfunction of myosin in these processes can lead to a range
of cardiac diseases with different presentations and
prognoses.
* For correspondence: Michael J. Greenberg, greenberg@wustl.edu.

Here, we review the complex functions and regulatory
mechanisms of cardiac myosin revealed by recent multiscale
studies. We highlight the roles played by myosin-based
contractility and mechanotransduction in supporting cardiac
development and their dysfunction in disease. Finally, we
discuss cardiac myosin as an emerging target for novel therapeutics developed for heart diseases.
Cardiac myosin structure
Cardiac myosin is a heterohexameric protein consisting of
two myosin heavy chains (MHCs), two regulatory light chains
(RLCs), and two essential light chains (ELCs) (Fig. 1A). Regions of myosin are frequently labeled by names derived from
proteolytic fragmentation, where limited proteolysis with
chymotrypsin yields heavy meromyosin (HMM) and light
meromyosin (LMM) fragments. HMM can further be digested to yield subfragment-1 (S1), monomeric myosin heads
containing either one or two of the light chains depending on
the protease used, and subfragment-2 (S2). Each MHC S1
head contains a nucleotide-binding pocket and an actinbinding interface. The head domain is followed by the light
chain-binding domain, a single alpha helix that ampliﬁes
small conformational changes in the nucleotide-binding site
into a large displacement known as the working stroke or
power stroke. The light chain-binding domain is mechanically
reinforced by an ELC and an RLC, where the ELC is proximal
to the head domain. The light chain-binding domain is followed by the S2 region, which helps to dimerize the two
MHCs. The ﬂexibility and length of the S2 region may impact
the unloaded shortening velocity of muscle (that is, the speed
at which the muscle length decreases in the absence of
external force) by imposing a drag load on ﬁlaments moving
at high velocities (1–3). As we will discuss later, S2 also plays
an important role in myosin autoinhibition. The S2 region is
followed by the LMM fragment (also known as the tail),
which contains a large coiled-coil tail domain that interacts
with tails of other myosin molecules to form the bipolar thick
ﬁlament.
While many muscle and nonmuscle myosin isoforms have
been crystallized (4, 5), it was not until 2015 that the ﬁrst
crystal structure of the cardiac myosin motor domain was
solved (6). The myosin shares many of the critical structural
elements common to myosins including loops involved in
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Figure 1. Cardiac myosin structure. A, schematic structure of cardiac myosin showing the regions named for proteolytic fragments heavy meromyosin
(HMM), light meromyosin (LMM), subfragment-1 (S1), and subfragment-2 (S2). Full-length myosin consists of two heavy chains (yellow and green), each
bound to an essential light chain (ELC, dark pink) and a regulatory light chain (RLC, light pink). The myosin heads (S1 region) contain the sites of ATP and
actin binding. The tails (LMM) are coiled coils that assemble into the thick ﬁlament. B, structure of the human cardiac myosin motor domain based on PDB
ID 4PA0, where the loops not resolved in the crystal structure were modeled using homology modeling. Structural domains related to the mechanical
power stroke, actin binding, and nucleotide binding to the active site are highlighted. For additional details on the structural mechanism of myosin force
generation, the reader is referred to (7).

nucleotide binding (e.g., P-loop, switch-1, and switch-2), actin
binding (e.g., the cardiomyopathy loop, loop 2, loop 4, and the
helix-loop-helix domain), and mechanical elements (e.g., relay
helix, SH1 and SH2 helices, and converter domain) (Fig. 1B).
The reader is referred to excellent reviews on myosin structure
and function for additional details on the role of these elements in mechanochemical coupling (7, 8). Crystal structures
of the cardiac myosin motor domain in both the pre-power
stroke and post-power stroke conformations revealed a fold
very similar to other myosin isoforms (6, 9, 10). This observation led to the question of how different myosin motors with
high degrees of structural conservation can have biochemical
properties (e.g., ADP release rate, duty ratio) that vary by orders of magnitude. A recent molecular dynamics study
demonstrated that small changes in myosin sequence can give
rise to changes in global protein ﬂuctuations, and that different
conformational ensembles explored by a myosin motor in
solution correlate with functionally relevant biochemical
properties (11). Moreover, recent technological advances in
the ﬁeld of cryo-electron microscopy enabled the
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determination of a structure of cardiac myosin bound to actin
(12). This structure revealed that several disordered loops in
the myosin structure are stabilized in the actomyosin complex,
including several residues frequently mutated in human
disease.
Cardiac muscle contraction
The fundamental contractile unit in cardiac muscle is the
sarcomere, which consists of interdigitated thin and thick ﬁlaments that lie between α-actinin-containing structures called
Z-discs (Fig. 2). Regions of the sarcomere are named for their
appearance as light and dark bands in electron micrographs of
muscle: myosin is localized to the dark A-band, whereas the
light band that contains actin is called the I-band. Myosincontaining thick ﬁlaments are organized into A-bands by
myomesin at the M-line and anchored to the Z-discs by titin.
In the C-zone of the sarcomere, cardiac myosin interacts with
cardiac myosin-binding protein C (cMyBP-C). cMyBP-C is
anchored to the thick ﬁlament by its C-terminal region,
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Figure 2. Cardiac myosin integration into the sarcomere. A, diagram of the sarcomere, drawn roughly to scale. Bands and discs observed by
electron microscopy are labeled. B, cartoon showing a zoomed-in view of the sarcomere within the C-zone. Elements are drawn roughly to scale.
Myosin heads in the super relaxed state (SRX) are bound to the thick ﬁlament backbone, whereas myosin heads in the disordered relaxed state (DRX)
are freed from the backbone. C, schematic structure of myosin in the autoinhibited, interacting heads motif (IHM) associated with the SRX (left and
center) and the DRX (right). In the IHM, the blocked head (yellow) interacts with the free head (green). It has been proposed that the IHM is stabilized by
cMyBP-C (blue), where phosphorylation of cMyBP-C reduces its interaction with myosin (center). Phosphorylation of the RLC (pink) and mechanical
forces each promote the formation of the DRX; however, it is important to note that they are not required for the formation of the DRX. Note that RLC
phosphorylation can occur on either one or both of the heads.

whereas the N-terminal region regulates muscle contraction
through its interactions with either the myosin head domain or
the thin ﬁlament. Thin ﬁlaments, consisting of actin ﬁlaments
decorated with proteins including tropomyosin and troponin,
are anchored to the Z-discs via their barbed ends. This
orientation of the actin ﬁlaments ensures that cardiac myosin,
which moves toward the barbed end of actin, will directionally
pull the Z-discs toward the center of the sarcomere, shortening
the distance between the Z-discs.
The force generated by a muscle is proportional to the
number of actin-bound myosins (termed “crossbridges”
because they bridge the thick and thin ﬁlaments) and the
average force per crossbridge. Each individual motor generates
1 to 5 pN of force (13); however, the collective motion of many
motors in the sarcomere produces higher forces. The number
of crossbridges bound to actin at a given time is the product of
the total number of available, active myosin heads, and the
duty ratio (i.e., the fraction of the biochemical cycle that a
given crossbridge remains bound to actin) (14). The power
output is the product of the shortening speed and the force. As
such, force production depends on both the kinetics of the
ATPase cycle and the mechanics of the motor. As discussed

below, these parameters can be dynamically tuned to match
the physiological loads of the body.

The actomyosin biochemical cycle
Myosin is an ATPase that utilizes energy drawn from ATP
hydrolysis to generate movement (15) (Fig. 3). Changes in the
myosin-bound nucleotide modulate the afﬁnity of myosin for
actin (16), where the myosin and actin can either be strongly
bound (i.e., force-generating or -bearing states) or weakly
bound (i.e., actomyosin is primarily dissociated but transiently
interacting through short-lived, weak electrostatic interactions
that do not bear load) (17–19). In the absence of nucleotide,
myosin and actin are strongly bound in a rigor complex. ATP
binding to actin-bound myosin causes actomyosin dissociation. Myosin hydrolyzes ATP to ADP and inorganic phosphate
and isomerizes to the pre-power stroke conformation, where
the head is primed to generate force. Myosin then rebinds to
actin, initiating the force-generating power stroke and triggering the release of inorganic phosphate. During the power
stroke, the light chain-binding domain rotates by 70 ,
generating a 4 nm displacement. ADP is then released and
J. Biol. Chem. (2021) 297(5) 101297
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Figure 3. The myosin mechanochemical cycle and its regulation. For simplicity, only one myosin head is shown. In the super relaxed state (SRX, blue
shaded box), myosin is autoinhibited. Force and RLC phosphorylation each promote the adoption of the disordered relaxed state (DRX). The thin ﬁlament
can lie in the blocked, closed, or open states, where switching between states depends on calcium and myosin binding. In the open state, myosin can bind
to and detach from the thin ﬁlament in a nucleotide-dependent manner. Bound and detached states are indicated by yellow and red shading, respectively.
Force-dependent steps are indicated by red arrows. Mechanical substeps of the working stroke and structural states (pre-power stroke and post-power
stroke) are labeled.

the light chain-binding domain rotates further to the postpower stroke state, generating an additional 2 nm displacement (20, 21) for a total displacement of 6 nm (22–26).
The transition to strong binding and the associated release
of phosphate is the slowest step in the myosin ATPase cycle
and the step associated with the largest release of free energy
(16). Actin binding accelerates the rate of phosphate release
from myosin by orders of magnitude; however, this transition
remains the rate-limiting step of the overall ATPase cycle in
the presence of actin (16). Although some structural studies
have indicated that phosphate release precedes the power
stroke (27, 28), recent optical trapping and spectroscopic
measurements suggested that the power stroke precedes
phosphate release (24, 29–31). Regardless of this order, the
primary steady-state intermediate of the ATPase cycle is a
state in which actin and myosin are dissociated and myosin is
bound to ADP and inorganic phosphate.
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While the rate of actin-activated phosphate release limits
the overall ATPase cycle, other biochemical rates determine
physiologically important parameters of muscle contraction,
including the shortening speed, force, and power output. The
unloaded shortening rate of a muscle is generally thought to be
limited by the rate of actomyosin crossbridge detachment (32,
33). Therefore, the rate of ADP release sets the rate of
unloaded shortening, since this rate limits crossbridge
detachment at physiologically relevant ATP concentrations
(34). The speed is also proportional to the size of the myosin
working stroke (32), which can be altered by disease-causing
mutations (21). It should be noted that other models of
muscle contraction have been proposed, including a recent
model where the speed depends on both attachment and
detachment kinetics (2). In this model, the speed is related to
the length and ﬂexibility of the S2 linker as well as the myosin
step size.
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Regulation of actomyosin-based force generation
While the basics of the myosin biochemical cycle have been
understood since the 1970s (16), our understanding of the
regulation of cardiac myosin has advanced greatly in the past
few years. These advances have been made possible by multiscale studies of increasing complexity and several technological innovations. These studies have given a more nuanced
understanding of how the heart ﬁne-tunes its power output
over various length and temporal scales, identiﬁed new
mechanisms of disease pathogenesis, and provided new avenues for the development of therapeutics for heart diseases.
Moreover, they identify mechanisms by which cardiac myosin
not only generates cardiac power output, but also plays a
critical role in its regulation.
Regulation of accessibility of myosin-binding sites on actin
Cardiac contraction is regulated from beat-to-beat by calcium (Ca2+). The calcium-dependent interactions between
the thick and thin ﬁlaments are regulated by troponin and
tropomyosin (Figs. 2 and 3) (35, 36). During diastole, the
relaxation phase of the cardiac cycle, intracellular calcium
levels are low and tropomyosin adopts the blocked state,
sterically blocking myosin-binding sites along the thin ﬁlament and preventing contraction. During myocyte activation,
intracellular cytoplasmic calcium levels rise, and calcium
binding to troponin C causes tropomyosin to move to the
closed position on the thin ﬁlament, partially exposing the
myosin-binding interface on actin. Tropomyosin can then
move into the open position, in which the myosin-binding
site is fully exposed. The binding of one myosin uncovers
adjacent myosin-binding sites on actin that were obscured by
tropomyosin, resulting in cooperative activation of the thin
ﬁlament. Myosin generates force during systole, the
contraction phase of the cardiac cycle, until cytoplasmic
calcium levels drop, leading to deactivation of the thin ﬁlament. Thus, the processes of muscle activation and relaxation
depend on both calcium and myosin binding to the thin
ﬁlament (35, 37–39).
Recent studies have shown that myosin-binding protein-C
(cMyBP-C) may play a role in tuning thin ﬁlament activation.
The reader is referred to a recent review on cMyBP-C for more
details on its structure and function (40). The N-terminal region of cMyBP-C can bind to the thin ﬁlament (41), shifting
tropomyosin into the open position (42–44). This shift reduces
the energy barrier for myosin strong binding, enabling force
generation at lower levels of calcium (45). This is consistent
with muscle ﬁber studies using cMyBP-C knockout mice (46)
and mice lacking the N-terminal region of cMyBP-C (47),
which each showed reduced thin ﬁlament activation in
response to calcium. Moreover, elegant experiments using
transgenic mice expressing an engineered construct of
cMyBP-C with an N-terminal region that can be cleaved and
exchanged with a recombinant cMyBP-C construct showed
that removal of the N-terminal region causes spontaneous
oscillatory contractions (47). These spontaneous oscillations

were damped when the N-terminal region was added back to
the cMyBP-C. Based on these results, it was proposed that
cMyBP-C binding to the thin ﬁlament helps to maintain
tropomyosin in the open position, preventing relaxation of the
muscle before calcium levels drop (48). This activation can be
dynamically tuned. Upon β-adrenergic stimulation, protein
kinase A (PKA) phosphorylates cMyBP-C, reducing the
binding of cMyBP-C to the thin ﬁlament and tuning the level
of thin ﬁlament activation (49, 50). We speculate that myosininduced movement of tropomyosin along the thin ﬁlament
may also increase the binding of cMyBP-C to the thin ﬁlament,
since it exposes cMyBP-C-binding sites along actin.

Regulation of the number of force-generating myosin heads
Although the regulation of molecular motors by autoinhibition has been recognized for a while (51–56), even in the
context of myosin II (57–61), recognition of the functional
importance of autoinhibition in striated muscle myosin has
emerged more recently. Key evidence of thick ﬁlament-based
regulation of striated muscle was provided by measurements
in Roger Cooke’s lab of the single turnover rate of ATP in
relaxed skeletal muscle (i.e., at low calcium) using a ﬂuorescent ATP analog, Mant-ATP (62). They observed biphasic
turnover kinetics, with one rate similar to that of ATP turnover of myosin S1 in solution in the absence of actin
(0.05 s−1) and a much slower rate (0.004 s−1). They proposed
that the fast and slow rates represent populations of myosins
in a disordered relaxed state (DRX) and super relaxed state
(SRX), respectively (62, 63). The SRX was later observed in
cardiac muscle (64).
It has been proposed that the biochemical SRX corresponds
with an autoinhibited structural state observed in cryoelectron microscopy reconstructions of thick ﬁlaments from
cardiac muscle, smooth muscle, and tarantula skeletal muscle
(59, 65–67). In this structure, the myosin heads fold back
toward the S2 region to form an asymmetric structure known
as the interacting heads motif (IHM) (Fig. 2). One head,
dubbed the blocked head, is locked in the pre-power stroke
state, and it interacts with its own S2 region. The primary
head–head interaction site, which is adjacent to the actinbinding region of the blocked head, interacts with the converter domain of the other, free head, locking both heads in
the autoinhibited state (68, 69). Interestingly, this structure
has many similarities to the autoinhibited state seen in isolated, full-length smooth muscle and nonmuscle myosin II
molecules (58, 60, 61).
Several pieces of evidence connect the biochemical SRX and
the IHM structural state. X-ray diffraction studies of intact
cardiac muscle ﬁbers demonstrated a correspondence between
the fraction of ordered myosin heads along the thick ﬁlament
backbone and the fraction of heads in the SRX measured
biochemically (68). Negative stain electron microscopy of
myosin motors also revealed a correlation between the fraction
of heads in the SRX and the fraction of heads that form an
autoinhibited structure. In addition, small-molecule
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compounds that altered the biochemical SRX induced a
similar change in the fraction of heads in the autoinhibited
state. Collectively, these data suggest a correspondence between the SRX and the IHM.
The IHM is likely stabilized by interactions between
myosin and cMyBP-C (70). Spudich noted that the cardiac
myosin head has a large, ﬂat region enriched with charged
residues that is likely involved in forming protein–protein
interactions, which he dubbed the “mesa domain” (69).
Many mutations that cause genetic cardiomyopathies are
found on the mesa domain (71). Part of the mesa forms the
interface of the IHM; however, another part of this region is
exposed. It was proposed that the exposed part of the mesa
interacts with cMyBP-C in the thick ﬁlament. Deletion of
cMyBP-C reduces the formation of the SRX (72). Moreover, it
was shown that an N-terminal fragment of cMyBP-C can
bind to myosin in solution, and that this binding promotes
the formation of the biochemical SRX (70). Phosphorylation
of cMyBP-C by PKA upon β-adrenergic stimulation decreases
the interactions between cMyBP-C and myosin, destabilizing
the SRX (73).
The fraction of myosins in the SRX can be dynamically
modulated by mechanisms that decrease the fraction of
myosin heads in the SRX, increasing the number of myosin
heads available to generate force (Figs. 2 and 3). For example,
RLC phosphorylation by myosin light chain kinase is essential
for the activation of smooth muscle and nonmuscle myosin II
isoforms, but not striated muscle myosins. In the heart, cardiac
contraction is modulated through a large gradient of RLC
phosphorylation between layers of the heart that has been
proposed to play a role in generating torque during blood
ejection (74). X-ray diffraction studies demonstrated that RLC
phosphorylation causes the myosin heads to move closer to the
thin ﬁlament, and that this modulates the kinetics of muscle
contraction (75–77). Recent studies demonstrated that RLC
phosphorylation destabilizes the SRX, increasing the population of the DRX state (70).
The fraction of myosin heads in the SRX can also be
regulated by mechanical force (78). Recent studies using
intact muscle ﬁbers demonstrated that stretching cardiac
muscle causes an increase in the fraction of available heads
(79, 80). This mechanosensitive release of myosin motors in
the SRX from the thick ﬁlament backbone might enable the
muscle to quickly and dynamically regulate the fraction of
heads in the SRX during times of increased workload
(80, 81). The force-dependent decrease in the SRX population results in generation of larger forces by myoﬁlaments at
longer sarcomere lengths, which, together with incompletely
understood thin ﬁlament-based mechanisms, underlies
length-dependent activation in cardiomyocytes (79–84).
Length-dependent activation contributes to the tissue-level
relationship between the extent of ventricular ﬁlling and
the strength of cardiac contraction, known as the Frank–
Starling law of the heart (85). The force-induced destabilization of the SRX can only be observed in the context of
myosin ﬁlaments, emphasizing the importance of multiscale
studies to fully understand the mechanisms intrinsic to
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myosin that help to regulate and ﬁne-tune the force and
power output of muscle.
Regulation of myosin motor function by mechanical forces
Mechanical forces that assist or resist the myosin power
stroke can affect the rates of biochemical transitions, thereby
tuning muscle force production and power output. This mechanical regulation tunes the myosin contractility on very fast
timescales (i.e., from power stroke to power stroke). This was
ﬁrst recognized in pioneering work by Hill and Fenn, who
noted that the heat released during muscle shortening was
greater during unloaded shortening than under high tension
(86, 87). In the case of muscle myosins, muscle ﬁber and optical trapping experiments have revealed that there are multiple force-sensitive transitions (Fig. 3) (20, 24, 88, 89). As
described earlier, the unloaded shortening speed of muscle is
limited by the rate of ADP release, the transition that limits
actomyosin dissociation at physiological ATP concentrations
(20, 34, 90). In the presence of loads that oppose the myosin
working stroke, the rate of ADP release slows, slowing the rate
of muscle contraction (20, 25, 91).
In addition to slowing ADP release, mechanical forces can
also modulate the number of force-generating crossbridges by
affecting both the isomerization to the strong binding state
and subsequent phosphate release (24, 88). Recent experiments using an ultrafast optical trap demonstrated that
increasing loads that either resist or assist the power stroke
can increase the rate of actomyosin dissociation before
myosin isomerization to the strong binding state (Fig. 3) (24).
This pre-power stroke detachment occurs at rates that are an
order of magnitude faster than the rate of ADP release.
Assisting and resisting forces have asymmetric effects on this
dissociation rate due to the stereospeciﬁc interactions
required for myosin cleft closure. Moreover, forces that resist
the power stroke can also increase the probability of phosphate rebinding and reversal of the power stroke. Taken
together, these three force-dependent pathways (slowing of
ADP release, preventing strong binding, and reversing the
power stroke) tune the speed, force, and power generated by
the muscle.
Regulation by transcriptional regulation of isoform expression
The contraction of cardiac myosin can be regulated transcriptionally by differential expression of MHC, ELC, and RLC
subunits. In the adult human heart, the primary ventricular
isoforms are MYH7 MHC (β-cardiac myosin), MYL3 ELC, and
MYL2 RLC, whereas the primary atrial isoforms are MYH6
MHC (α-cardiac myosin), MYL4 ELC, and MYL7 RLC (92).
While these are the primary isoforms expressed, multiple
isoforms are expressed within a ventricle, and heteromolecules
(e.g., a myosin dimer made of one MYH7 MHC and one MYH6
MHC) have been observed (93). Evidence from murine hearts
showed that the expression of MYH6 and MYH7 MHCs in the
ventricles can vary spatially with enrichment in substructures
within the heart (94). The exact composition of MHC, RLC,
and ELC can tune the kinetics and mechanics of the myosin.
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For example, MYH7 MHC has a signiﬁcantly slower ADP
release rate and unloaded shortening speed compared with
MYH6 MHC (95, 96), but MYH7 motors can generate a larger
ensemble force (97). Similarly, the size of the working stroke of
muscle myosins depends on the ELC isoform (98).
The expression of myosin isoforms changes over time
during development and disease. For example, in the human
heart, the fraction of MYH7 MHC expressed in both the atria
and ventricles increases between the fetal and adult hearts (99).
The fraction of MYH7 MHC also changes during disease. In
the ventricle, MYH7 MHC expression increases from 93% in
the healthy heart to 100% MYH7 MHC in the failing heart
(100, 101), and the amount of MYH7 MHC in the atria increases from 14% in the healthy heart to 50% in the failing
heart. Therefore, changes in the expression of different myosin
isoforms play an important role in modulating cardiac
contractility during long-term cardiac remodeling associated
with development and disease.

Myosin mechanosensing
Beyond its role generating cellular tension, cardiac myosin is
part of the machinery necessary for sensing and transducing
molecular forces. Thus, disrupted cellular tension affects
cellular processes beyond muscle contraction. For example,
myosin-generated tension is required to support sarcomere
organization in cardiomyocytes, although the respective roles
of cardiac and nonmuscle myosins in sarcomere assembly and
maintenance remain somewhat controversial (102, 103).
Treatment with blebbistatin, which disrupts myosin-driven
contraction, leads to loss of sarcomere content in human
induced pluripotent stem cell–derived cardiomyocytes
(hiPSC-CMs) (102). Milder disruptions to myosin-generated
force by pathogenic mutations in sarcomeric proteins can
lead to sarcomeric remodeling (104, 105).
Myosin mechanosensing also plays a direct role in development. The stiffness of cardiac tissue increases during embryonic development, where adult tissue is 10× stiffer than
the embryonic heart (106). The myosin-driven spontaneous
contraction of cardiomyocytes isolated from embryonic chick
hearts is optimized on substrate stiffnesses similar to that of
embryonic heart tissues (107). Alteration of tissue elasticity via
treatment of isolated embryonic heart tubes with collagenase
(to soften) or a cross-linking enzyme (to stiffen) each impaired
spontaneous beating, demonstrating that myosin contractile
function is exquisitely matched to matrix elasticity (107).
Moreover, myosin contractility plays a role in feedback loops
of signaling pathways driving the cell cycle in embryonic hearts
(108). Therefore, perturbations that affect myosin function can
effect changes beyond force generation.
Altered myosin contractility leads to disease
Given its central role in driving circulation, functional cardiac myosin is essential for life. Actomyosin function can be
modulated by many factors, including posttranslational modiﬁcations (109–112) and genetic mutations. A large number of
mutations in cardiac myosin genes, including both the heavy

and light chains, are associated with human disease, including
familial cardiomyopathies (hypertrophic, dilated, and restrictive) (113–115), left ventricular noncompaction (116), skeletal
myopathies (117), developmental defects (e.g., atrial septal
defects) (118), and electrophysiological disorders (e.g., sick sinus syndrome) (119). The majority of these pathogenic mutations are point mutations that change myosin’s properties
without rendering it nonfunctional, since major changes are
incompatible with life. Interestingly, different mutations within
the same gene can lead to different diseases, and the
complexity of the resulting disorders clearly demonstrates that
these mutations affect processes beyond just force generation.
The variety of diseases caused by myosin mutations suggests
that the context and speciﬁc effects of the mutation on molecular function are important for both the disease pathogenesis and progression (120). Below, we discuss two different
classes of diseases caused by mutations in cardiac myosin.
Familial cardiomyopathies
Familial cardiomyopathies, leading causes of sudden cardiac
death and heart failure in young people, are caused by mutations in several genes, including those encoding myosin heavy
chain (MYH7), ELC, and RLC. MYH7 mutations were the ﬁrst
identiﬁed genetic causes of familial hypertrophic cardiomyopathy (HCM) (121, 122), a heart disease characterized by left
ventricular hypertrophy and impaired cardiac relaxation (115).
Since then, it has been shown that mutations in cardiac myosin
(MHC, RLC, and ELC) (123) can also cause dilated cardiomyopathy (DCM), which involves left ventricular dilation and
impaired systolic function (124).
A central challenge for the ﬁeld is to distinguish primary
drivers of disease from downstream and/or secondary effects
(120). This is particularly challenging since these disorders are
protean in nature, where different pathways are activated over
the course of these progressive diseases (often years to decades). A mechanistic understanding is important for the
design of potential precision medicine therapeutics. The
involvement of mutations in myosin and other sarcomeric
proteins (125, 126) in HCM and DCM suggests altered cardiac
contractility as a pathogenic mechanism. The integral of tension development over time in both mice and hiPSC-CMs
predicted whether a given mutation leads to hypertrophic or
dilated cardiomyopathy better than measurements of calcium
handling (127), where increased contractility is associated with
HCM and decreased contractility with DCM. Importantly,
modulation of the tension integral can prevent pathogenic
remodeling (127, 128). Moreover, recent studies from our lab
used a computational model of cardiac contraction (129) to
show that altered thin ﬁlament regulation can predict changes
in cardiac contractility that are consistent with those seen in
cardiomyocytes (105).
Due to the inherent complexity of the disease pathogenesis,
there has been a strong push to develop model systems that
recapitulate the disease phenotype and enable functional
studies of human disease-causing mutations in vitro. Excellent
transgenic mouse studies have provided insights into the
J. Biol. Chem. (2021) 297(5) 101297
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disease pathogenesis; however, they have the limitation that
mouse ventricles express primarily MYH6 MHC, not MYH7
MHC like in the human heart (130). Due to functional differences between MYH6 and MYH7 MHCs, the presentation and
biophysical defects associated with a given mutation can vary
depending on the MHC backbone (131–136). Although MYH7
MHC protein can be obtained from patient biopsy samples,
there are several associated challenges, including small quantities and unknown ratios of mutant to wild-type protein, which
can lead to inconsistent results (137, 138). Thus, one of the
principal challenges to studying human MYH7 mutations
in vitro has been the lack of recombinant expression system.
While many myosin isoforms, including nonmuscle myosin-II
and smooth muscle myosin, can be expressed using the baculovirus/Sf9 system, striated muscle myosins cannot due to the
lack of muscle-speciﬁc chaperones (139–141). The recombinant
expression of striated muscle myosins in murine myoblast cells
(C2C12) was a major step forward that enabled the production
of sufﬁcient quantities of soluble recombinant protein for
functional and structural studies (6, 95, 142).
Studies using recombinant human cardiac myosin revealed
that cardiomyopathy-associated mutations can directly affect
contractility at the level of individual motors (143, 144). Mutations that cause HCM typically increase molecular contractility, whereas DCM-causing mutations decrease contractility
(123). However, some of these effects only become apparent
when looking at reconstituted systems of increasing
complexity. For example, studies using recombinant R403Q
cardiac myosin in the MYH7 MHC backbone observed
increased velocity in an unregulated in vitro motility assay;
however, the difference in velocity disappeared when regulated
thin ﬁlaments were used (145). Furthermore, the intrinsic
force generated by an R403Q myosin motor was lower than
that generated by wild-type myosin, and altogether the results
were consistent with reduced contractile function for R403Q
motors (145). This might have suggested that hypercontractility in HCM caused by R403Q can be a secondary
compensatory mechanism to counteract reduced myosin
function, rather than a primary driver of disease. However, it
was later demonstrated that the R403Q mutation destabilizes
the myosin SRX, leading to increased contractility (70, 146).
Furthermore, the R403Q mutation ablates binding of cMyBPC, which promotes adoption of the SRX in wild-type myosin
(146). This mechanism of increased contractility via an increase in the number of available myosin heads, regardless of
the intrinsic contractility of each myosin head, has also been
demonstrated for several other HCM-associated mutations in
cardiac myosin (146–149). In contrast, DCM-causing mutations tend to directly affect the force-generating capacity of
individual myosin motors (150, 151). That said, the effects of a
given mutation on protein function are often complex and may
be best described by a combination of effects rather than a
single mechanism. However, the grouping of mutations by
common effects is useful for our fundamental understanding
of disease pathogenesis as well as to aid the development of
novel therapeutics that target speciﬁc disease mechanisms, as
described in a recent review (120) and discussed below.
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Atrial septal defect
Mutations in MYH6 MHC, the primary atrial myosin isoform, can lead to atrial septal defect, a congenital heart malformation (118, 152, 153). During development, MYH6 is
required for the proper formation of the atrial septum, the wall
between the two atrial chambers (118). Mutations in MYH6
that cause atrial septal defect appear to affect the interaction
between the myosin heavy chain and the RLC (118) or between
myosin and actin (152, 153). In contrast to cardiomyopathies,
which can take decades to develop into symptomatic disease
despite the presence of the mutation since birth, atrial septal
defects are congenital heart defects. This is consistent with
actomyosin-generated tension during development driving
cellular function and organization.

Altered contractility results in downstream
mechanobiological dysfunction
Although pathogenic point mutations in cardiac myosin can
affect cardiac contraction, changes in contractility in isolation
are insufﬁcient to explain the disease pathogenesis and
complexity of presentation. At the molecular scale, defects in
function due to pathogenic mutations are usually subtle, which
is not surprising because major changes would be incompatible with life. In the case of familial cardiomyopathies, the
mutant protein is expressed over the entire lifetime of the
patient; however, pathological cardiac remodeling often does
not occur until adolescence or later (154). There is evidence
that genotype-positive patients show alterations in cardiac
contractility before the development of pathogenic remodeling
and symptomatic disease (155, 156). As such, mutationinduced changes in myosin contractility can be the initial insults that drive the early disease pathogenesis, leading to the
activation of adaptive pathways that initially normalize cardiac
function, but eventually transition to maladaptive remodeling.
These maladaptive responses drive the disease symptoms and
progression. Altered calcium handling (157), increased ﬁbrosis
(158), myoﬁbrillar disarray (159), aberrant electrophysiology
(160), and cellular hypertrophy (161) are all downstream
consequences of the initial insult of altered contractility.
Similarly, in the case of atrial-septal defects caused by
MYH6 mutations, changes in myosin-based force production
affect cardiac development. In this case, the disease phenotype
is likely due to changes in the interactions between cells, not to
changes in ejection fraction. The alteration of cellular function,
gene expression, and tissue morphology by mutation-induced
changes in myosin-based tension generation highlight the
important role that cardiac myosin plays in mechanobiological
signaling pathways.
Pathogenic mutations in myosin can also drive changes in
tissue mechanics. Altered tissue stiffness plays a role in heart
failure, where the prevalence of detyrosinated microtubules
results in increased cardiomyocyte stiffness and impaired
contractility (162). Higher levels of microtubule detyrosination
were found in tissue isolated from HCM patients with sarcomeric mutations compared with sarcomere mutation-negative
HCM patients, suggesting that microtubule detyrosination

JBC REVIEWS: Cardiac myosin in health and disease
plays a role in the downstream pathogenesis of HCM caused
by mutations in sarcomeric proteins (163).
Finally, it is important to note that disrupted force generation can affect processes beyond the myocyte. An example of
this is the activation of the ﬁbroblast-to-myoﬁbroblast transition by mechanical tension (164). Multiple stimuli that alter
cardiac contraction (e.g., hypertension, mutations, aortic stenosis) can drive the development of hypertrophy and myoﬁbroblast activation. Myoﬁbroblasts secrete large amounts of
extracellular matrix, contributing to ﬁbrosis frequently seen
with cardiomyopathies (165). Therefore, when considering the
downstream effects of myosin mutations on disease, it is
important to consider that these effects can be long-lasting and
extend beyond the myocyte.

Small molecules that target myosin contractility
Due to its role in driving and regulating heart contraction, as
well as its dysfunction in disease, cardiac myosin has emerged
as a drug target. There are several myosin-binding compounds
in development and in clinical trials that target cardiac
contractility either directly or through its regulatory mechanisms (Fig. 4).
Activators of cardiac contraction for systolic dysfunction
There are several conditions that can lead to heart failure
with reduced systolic function, including coronary artery disease, myocardial infarction, myocarditis, and dilated cardiomyopathy (166). The majority of current therapeutics alleviate
symptoms and target prevention of additional adverse
remodeling; however, the transplant-free survival rate is low.
Moreover, many of these therapeutics show limited efﬁcacy in
pediatric heart failure (167). Therefore, there is an outstanding
clinical need to develop therapeutics to improve outcomes for
patients, or patient subpopulations, with systolic heart failure.

Omecamtiv mecarbil (OM) was the ﬁrst small-molecule
therapy targeting cardiac myosin (168). It was discovered in
a high-throughput screen for compounds that increase the
actin-activated ATPase rate of cardiac myosin by increasing
the rates of ATP hydrolysis and phosphate release. OM binds
near the myosin converter domain, and therefore, exerts its
effects on the nucleotide-binding pocket allosterically. Studies
in isolated myocytes showed improved systolic function
without changes to the calcium transient. Moreover, the recent
GALACTIC-HF study demonstrated improved outcomes of
patients with heart failure in phase 3 clinical trials (169).
Given its effects on the myosin ATPase rate, OM was
originally proposed to act as a myosin activator; however,
further studies revealed that its biophysical mechanism of
action is more complicated than originally realized. While OM
increases the actin-activated ATPase rate of unregulated thin
ﬁlaments, it acts as an inhibitor when examined using regulated thin ﬁlaments at high calcium (170). Moreover, OM
causes a dramatic 20-fold reduction in myosin’s motility rate,
suggesting a complex mechanism of action (171). Recent optical trapping and transient kinetics experiments demonstrated
that OM causes cardiac myosin to enter a noncanonical
pathway with a long-lived strong binding state (25, 172).
Moreover, OM-bound myosins do not generate a productive
working stroke (25, 173). Thus, OM uncouples the kinetics
and mechanics of the working stroke of individual motors,
leading to reduced motile function.
Given that OM appears to reduce actomyosin detachment
kinetics and inhibit the working stroke, how does it increase
cardiac contractility in myocytes and patients? These seemingly contradictory results could be resolved by two nonexclusive mechanisms revealed by looking at systems of
increasing complexity. The ﬁrst mechanism involves thin
ﬁlament activation. As mentioned earlier, thin ﬁlament activation can be accomplished by both calcium and myosin

Figure 4. Pharmacological agents targeting cardiac myosin. Chemical structures, mechanisms, and current clinical trial status of myosin-targeting drugs
that treat systolic (blue shading) or diastolic (red shading) dysfunction.
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binding. By increasing the lifetime of the strongly bound state
of cardiac myosin, OM keeps the thin ﬁlament in an activated
state, leading to increased contractility (25). This result is
supported by studies from muscle ﬁbers showing that OM is
most effective over a narrow range of dosages (174). At low
OM concentrations, OM-bound crossbridges activate the thin
ﬁlament while crossbridges without OM continue to power
contraction, leading to increased force production. At higher
concentrations of OM, the fraction of OM-bound unproductive crossbridges increases, reducing the force production. In
this context, OM is better characterized as a thin ﬁlament
activator rather than a myosin activator. In the second
mechanism, OM decreases the fraction of myosin heads in the
SRX, which increases force production by the muscle by
increasing the number of available heads (175). These two
mechanisms of OM action, thin ﬁlament activation and SRX
destabilization, combine to increase cardiac contraction.
The effects of OM could be speciﬁc to mutations. An
elegant example of this was the demonstration that despite
suppressing the working stroke of wild-type myosin, OM
rescues the reduced working stroke of myosin carrying the
R712L mutation (21). This surprising ﬁnding was suggested to
result from OM binding to the post-power stroke state of
R712L myosin rather than the pre-power stroke state, highlighting the complexity of the therapeutic mechanism of OM
and of myosin force generation more broadly. It also raises the
possibility that OM may work for some mutations better than
others, highlighting the importance of precision medicine
approaches.
Recently, a new small-molecule compound, danicamtiv, was
discovered as a myosin activator (176). While the details about
this compound are still sparse, it appears to work by increasing
the myosin ATP turnover rate, improving systolic performance
without affecting diastolic tension (176, 177). Danicamtiv is
currently in phase 2 clinical trials (177).
Another intriguing potential therapy for systolic heart failure is the use of deoxy-ATP (dATP) (178). In contrast to
OM and danicamtiv, which were identiﬁed in high-throughput
screens of small molecules that alter myosin contractility,
dATP is a naturally occurring ATP analog. dATP binds to the
myosin ATPase-binding site, where it can compete with the
binding of ATP. The steady-state maximum actin-activated
ATPase rate of myosin is higher for dATP than for
ATP (178, 179). In contrast to OM, dATP increases the
unloaded shortening velocity without affecting the isometric
tension in muscle ﬁbers (178). Although dATP binds to the
myosin nucleotide-binding site, the effects of the drug on the
structural dynamics of actomyosin are more subtle than
initially thought. Molecular dynamics simulations revealed
that binding of dADP and Pi, the hydrolysis products of dATP,
induces allosteric changes in the myosin actin-binding site that
increase electrostatic interactions between myosin and actin,
enhancing the crossbridge attachment rate (180). By increasing
the attachment rate of myosin, this increases the number of
bound, force-generating crossbridges.
One interesting aspect of dATP therapy is that dATP is a
naturally occurring compound, produced by ribonucleotide
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reductase. As such, its therapeutic use is not conﬁned to
administering the compound directly to patients. Strategies to
introduce dATP into cardiomyocytes via overexpression of
ribonucleotide reductase have been described, demonstrating
the potential of cardiac-speciﬁc delivery using gene therapy
(181–183). Overexpression of dATP has been demonstrated to
improve contractility in several animal models (184–187), as
well as in human patient-derived tissue (188).
Inhibitors of cardiac contraction for HCM
As mentioned earlier, HCM is typically associated with
hypercontractility, and therefore, compounds reducing
contractility could help counteract the effects of diseasecausing mutations. Most current treatments for HCM are
palliative in nature. For patients with outﬂow tract obstruction,
they are treated with myectomy and drugs, which improve
hemodynamics (e.g., beta blockers, calcium channel blockers,
and disopyramide) while for nonobstructive patients, there are
no therapies (189). Recently, a new small-molecule therapy,
mavacamten (190), was identiﬁed from a high-throughput
screen for compounds that decrease myosin’s ATPase rate in
myoﬁbrils. This compound directly and speciﬁcally binds to
cardiac myosin. X-ray diffraction, biochemical, and electron
microscopy studies have revealed that mavacamten decreases
myosin contractility by stabilizing the SRX (68). As such, it
decreases contractility by reducing the number of available
myosin heads. Mavacamten has shown promising results in
phase 3 clinical trials (191).

Summary and future outlook
Although cardiac myosin has been thoroughly studied for
decades, ongoing studies across scales of organization have
revealed new mechanisms of myosin function and dysfunction
that have enabled the development of promising therapeutic
candidates. There are still many unanswered questions and
challenges in this exciting ﬁeld (Box 1). The structural and
biochemical mechanisms by which myosin senses and transduces force are still largely unknown. Understanding of these
mechanisms is crucial to understand the physiological role of
cardiac myosin, as well as how dysregulation of myosin
Box 1. Outstanding questions for the ﬁeld
How is entry into the SRX regulated?
What structural mechanisms are involved in force sensing by myosin
molecules and thick ﬁlaments?
Which signaling pathways are regulated by myosin mechanobiology,
and how do they become dysregulated in disease?
How do posttranslational modiﬁcations of myosin and its binding
partners tune myosin function over time during development and
disease pathogenesis?
How do different disease-causing mutations in myosin lead to activation of different downstream pathways?
Can myosin mutations be binned into groups that will positively
respond to a given therapeutic in order to improve patient outcomes
through a precision medicine approach?
How do speciﬁc mutations affect allosteric coupling within myosin, and
can this information explain why these myosin variants cause a given
disease?
What are the structural mechanisms of the new drugs that target
myosin function?
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contraction and mechanotransduction contribute to cardiac
disease. Furthermore, deeper understanding of disease mechanisms could guide the development of precision medicine
approaches to treat patients. Although patient-speciﬁc treatments are likely unrealistic, it might be possible to bin mutations into groups that will positively respond to a given
therapeutic (120). To realize the promise of this precision
medicine approach, we also need to better understand the
structural mechanisms of current and emerging drug compounds that target myosin function. Future work might also
elucidate how speciﬁc mutations affect allosteric coupling
within myosin, potentially expanding our ability to target
cardiac myosin therapeutically. Addressing these gaps in our
understanding will require the development of new experimental and computational methods that span scales of organization and faithfully recapitulate important aspects of
myosin contractility. This is an exciting time for the ﬁeld to ask
basic science questions, with the possibility of translating these
ﬁndings into improved treatment of devastating diseases.
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